ArticleDrug safety2020
Should Patients Receiving ACE Inhibitors or Angiotensin Receptor Blockers be Switched to Other Antihypertensive Drugs to Prevent or Improve Prognosis of Novel Coronavirus Disease 2019 (COVID-19)?
Article in Drug safety, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- NSAIDs and COVID-19: A Systematic Review and Meta-analysis.Drug safety · 2021Pooled it
- A systematic review and meta-analysis to evaluate the clinical outcomes in COVID-19 patients on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.European heart journal. Cardiovascular pharmacotherapy · 2021Pooled it
- The Role of Immunosenescence and Inflammaging in the Susceptibility of Older Adults to SARS-CoV-2 Infection.Current pharmaceutical biotechnology · 2026Review
- Trends in medicine utilisation in public and private healthcare facilities before and during COVID-19: a nationwide analysis of medicine procurement and sales data, 2018-2022.Journal of pharmaceutical policy and practice · 2024Article
- The use of non-steroidal anti-inflammatory drugs (NSAIDs) in COVID-19.NPJ primary care respiratory medicine · 2022Review
- Drug-based therapeutic strategies for COVID-19-infected patients and their challenges.Future microbiology · 2021Review
- Case series of COVID-19 patients from the Qinghai-Tibetan Plateau Area in China.World journal of clinical cases · 2021Article
- Enhancing Pharmacovigilance from the US Experience: Current Practices and Future Opportunities.Drug safety · 2021Review
- Impact of Chronic RAAS Use in Elderly COVID-19 Patients: A Retrospective Analysis.Journal of clinical medicine · 2021Article
- Effect of renin-angiotensin-aldosterone system inhibitors on Covid-19 patients in Korea.PloS one · 2021Observational
- COVID-19 and the elderly: insights into pathogenesis and clinical decision-making.Aging clinical and experimental research · 2020Review
- Does Ibuprofen Worsen COVID-19?Drug safety · 2020Article
- Severe respiratory SARS-CoV2 infection: Does ACE2 receptor matter?Respiratory medicine · 2020Review
- Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives.Frontiers in pharmacology · 2020Review
- Molecular Mechanisms Lead to Sex-Specific COVID-19 Prognosis and Targeted Therapies.Frontiers in medicine · 2020Review
- Article
- [Renin-Angiotensin-Aldosterone System Inhibitors should not be suspended due to SARS-CoV-2 Infection].Archivos peruanos de cardiologia y cirugia cardiovascularArticle
Corrections and comments
- Comment on
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.